Archived: 13th Winter Conference
on Medicinal & Bioorganic Chemistry
January 22nd - 26th 2017
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 22nd 2017
MBCF Drughunter Award
Program Chair: Matthew M. Hayward, Pfizer
Discovery of Xeljanz
Drug Discovery in Autoimmunity
Program Chair: Timothy Richardson & Daniel Dairaghi, Eli Lilly
CCR1 Antagonist
Discovery of GDC-0853: A Highly Potent, Selective, and Non-Covalent Btk Inhibitor
Discovery of VTP-43742, A RORgt Inverse Agonist for the Treatment of Psoriasis
Peptide Antagonists of Kv1.3
Monday, January 23rd 2017
Liquid Biopsy Platforms as Biomarkers in Oncology Clinical Trials and as Companion Diagnostics
Program Chair: Daniel Flynn, Deciphera Pharmaceuticals
Detecting Circulating Tumor Cells in Clinical Trials – Making Circulating Tumor Cells Glow using a Telomerase-based Assay
Accelerating Clinical Trials using NGS Liquid Biopsy
Using ctDNA Biomarkers in Ignyta’s Clinical Trials: Detecting Activating Alterations, Monitoring Drug Efficacy, and Detecting Resistance Mechanisms
Bringing Exosome Liquid Biopsy Technology into the Realm of Routine Clinical Use
Cell Free DNA Analysis of NSCLC Patients as a Paradigm for Clinical use of Liquid Biopsies
Advances in PET Imaging
Program Chair: Mike VanNieuwenhze, Indiana University / Shane Krsha, Merck
Cutting-Edge PET Radiochemistry Methodologies Applied to Drug Development
Enabling Late Stage Fluorination Methods for the Discovery and Radiosynthesis of PET Imaging Agents
Development of PET Imaging Tracers for Neuroscience Applications
Empowering Preclinical PET Imaging: Facile and User-Friendly 18F-labeling of Complex Molecules
Tuesday, January 24th 2017
Advances in Modern Synthetic Methods
Program Chair: Victor Snieckus, Queen’s University
Converting a Medicinal Chemistry Synthesis into a Manufacturing Process
C-H Functionalization Methods as Cutting-Edge Synthesis Tools for Medicinal Chemists
Hydrophosphinations of Strained Rings
Recent Forays in Methods Development and Complex Molecule Synthesis
Post-Phenotypic Screen Target Identification
Program Chair: Philippe Nantermet & Scott Wolkenberg, Merck
Target ID Successes and Lessons
Computational Approaches to Target ID Using Large Scale Protein-Ligand Modeling
A Chemoproteomic Approach to Identify Drivers of BACE1 Inhibitor Ocular Toxicity
The Splice is Right: Phenotypic Drug Discovery and Target ID for Spinal Muscular Atrophy
Wednesday, January 25th 2017
Biophysical Tools in Drug Discovery and Chemical Biology
Program Chair: Lyn Jones, Pfizer
Light-controlled Modulation of Gene Expression by Chemical Optoepigenetic Probes
Tracking Drug Action by Chemical Proteomics
Principles and Applications of DNA-Encoded Library Technologies
Biophysical and Chemical Methods to Interrogate Drug-Target Engagement
General Session | Medicinal and Synthetic Chemistry
Program Chair: Anthony Barrett, Imperial College / Matthew M. Hayward, Pfizer
Merck Drug Discovery Enabled
Structure-based drug design with G protein-coupled receptors: The discovery of Highly Selective M1 Agonists
Accounting for Lysosomotropism as a Strategy for Prioritizing Selective Inhibitors of BACE
The Discovery of a New Generation of Potent and Selective PI3Kδ Inhibitors
Chemically Non-Reactive Glycine Sulfonamide Inhibitors of Diacylglycerol Lipase
Modern Chemistry: Tools to Enable the Practicing Chemist
Preparation and Biological Evaluation of trans-Cyclopropyl-linked BACE1 Inhibitors
Thursday, January 26th 2017
Viral Diseases Eradication
Program Chair: Philippe G. Nantermet, Merck
Invention of Grazoprevir, a Hepatitis C NS3 Protease Inhibitor
Inhibition of the HCV Polymerase NS5B as a Means Towards Curative Therapy
The Discovery of HCV NS5A Replication Complex Inhibitors
Hepatitis B: Is There a Path to a Cure?
What will it take to Eradicate HIV: A Drug Discovery Perspective
KEYNOTE PRESENTATION
Program Chair: Professor Anthony GM Barrett, Imperial College
Tackling a Pandemic Disease: A History of HIV Drug Discovery at Merck
Media Sponsors
